Skip to content

Anti-Mullerian Hormone Changes After Laparoscopic Ovarian Cystectomy for Endometrioma Compared With the Non-ovarian Conditions

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01919333
Enrollment
56
Registered
2013-08-09
Start date
2012-12-31
Completion date
Unknown
Last updated
2013-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Reserve

Brief summary

This aim of the study is to evaluate the impact of endometrioma and laparoscopic cystectomy on ovarian reserve as measured by serum antimullerian hormone and to study the different effects of levels of serum antimullerian hormone between laparoscopic cystectomy and the non-ovarian pelvic surgery.

Interventions

None listed

Sponsors

Thammasat University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* • Participants must be between the ages of 18 - 45 during enter the study . * Every participants have to completely understand the process of this study and have written informed consent . * Having regular menstrual cycles (21-35 days) at the time of operation * no evidence of any other endocrine disorders such as diabetes mellitus, thyroid dysfunction, hyperprolactinemia, congenital adrenal hyperplasia, Cushing's syndrome, or adrenal insufficiency. * undergo laparoscopic ovarian cystectomy or laparoscopic non- ovarian pelvic surgery for benign pelvic disease * No previous history of adnexal surgery * No any suspicious findings of malignant ovarian diseases * Never taking any medication such as oral pill and hormonal drugs within 3 months before the enrollment. * pathological diagnosis of excised ovarian tissue confirm as endometriotic cyst in study group and other benign pelvic disease in control group

Exclusion criteria

* polycystic ovarian syndrome according to the Rotterdam criteria * pathological report as the malignant diseases * have operation conversion to open-laparotomy

Design outcomes

Primary

MeasureTime frame
Serum AMH levels6 months

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026